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Summary
 
The many binding studies of monoclonal immunoglobulin (Ig) produced by plasmacytomas
have found no universally common binding properties, but instead, groups of plasmacytomas
with specific antigen-binding activities to haptens such as phosphorylcholine, dextrans, fructo-
furanans, or dinitrophenyl. Subsequently, it was found that plasmacytomas with similar binding
chain specificities not only expressed the same idiotype, but rearranged the same light (V
 
L
 
) and
heavy (V
 
H
 
) variable region genes to express a characteristic monoclonal antibody. In this study,
we have examined by enzyme-linked immunosorbent assay five antibodies secreted by sili-
cone-induced mouse plasmacytomas using a broader panel of antigens including actin, myosin,
tubulin, single-stranded DNA, and double-stranded DNA. We have determined the Ig heavy
and light chain V gene usage in these same plasmacytomas at the DNA and RNA level. Our
studies reveal: (a) antibodies secreted by plasmacytomas bind to different antigens in a manner
similar to that observed for natural autoantibodies; (b) the expressed Ig heavy genes are re-
stricted in V gene usage to the V
 
H
 
-J558 family; and (c) secondary rearrangements occur at the
light chain level with at least three plasmacytomas expressing both 
 
k
 
 and 
 
l
 
 light chain genes.
These results suggest that plasmacytomas use a restricted population of B cells that may still be
undergoing rearrangement, thereby bypassing the allelic exclusion normally associated with ex-
pression of antibody genes.
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P
 
ristane- and mineral oil–induced mouse plasmacytomas
(PCs)
 
1
 
 have proved to be invaluable in the study of Ab
diversity, as well as in the chromosomal translocations asso-
ciated with the development of late-stage B cell tumors.
Virtually all mouse PCs exhibit a nonrandom chromosomal
translocation between the Ig heavy chain or light chain
gene and the 
 
c-Myc
 
/
 
Pvt 1
 
 gene locus (1). As the original
source of homogeneous Abs, PCs exhibit allelic exclusion
and express a single unique heavy chain and light chain Ig
molecule. Although some PCs have demonstrated reactiv-
ity to specific Ags (i.e., DNP, 
 
a
 
1,3- and 
 
a
 
1,6-dextrans,
phosphorylcholine, levan, and 
 
b
 
2,1- and 
 
b
 
2,6-fructofura-
nans), a single predominant Ag or hapten target has not sur-
faced despite nearly three decades of research (2). In earlier
studies, we found that natural polyreactive autoantibodies
(NAAs) are an important component of the normal B cell
repertoire, and that hybridomas derived from the spleens of
BALB/c mice frequently exhibited polyreactivity to a panel
of Ags including actin, myosin, tubulin, single-stranded
(ss)DNA, and double-stranded (ds)DNA (3–5). Although
NAAs are of low affinity and are encoded by essentially
germline V region sequences (6), pathogenic Abs impli-
cated in autoimmune disease are monospecific with higher
affinity, and exhibit Ag-driven somatic mutation. In addi-
tion, considerable data have accumulated in humans indi-
cating that the autoreactive repertoire frequently undergoes
malignant transformation. This evidence has accumulated
in studies of chronic lymphocytic leukemia (CLL), follicu-
lar non-Hodgkin lymphomas (FNHLs), and monoclonal Ig
(for review, see reference 7). Paradoxically, the NAA spec-
ificity frequently found among human monoclonal Ig has
not yet been reported in mouse PCs. In this report, we
 
1
 
Abbreviations used in this paper:
 
 CLL, chronic lymphocytic leukemia; ds,
double-stranded; g, generation; GC, germinal center; IVS, intervening
sequence; NAA, natural polyreactive autoantibody; PC, plasmacytoma;
R, replacement; RAG, recombination activating gene; RT, reverse tran-
scription; S, silent; SI, silicone-induced PC; ss, single-stranded. 
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have searched for and found polyreactivity to several Ags,
including myosin, dsDNA, and ssDNA in BALB/c sili-
cone-induced PCs (SIPCs) of primarily the IgA heavy
chain class.
Since the analysis of V region nucleotide sequences can
also provide insight into the stage of B cell development at
which clonal expansion occurs, as well as the putative role
that an Ag-driven process could play in the selection of
malignant B cell tumors, we have examined and identified
restricted V region usage in the SIPC tumors. We have also
observed Ab diversification in the form of secondary rear-
rangements that may be targeting the B cell population
(B-1) in the periphery, apparently in an attempt to diverge
from the polyreactive response and possible autoimmunity.
 
Materials and Methods
 
Tumors.
 
SIPCs were generated by three successive inocula-
tions (on days 0, 60, and 120) of silicone gel into the peritoneal
cavity of BALB/c or BALB/c.DBA/2N-Idh1-Pep3 congenic
mice (8). The latency times for first generation tumors were
SIPC3301 (227 d), SIPC3308 (190 d), SIPC3282 (152 d),
SIPC3336 (220 d) and SIPC3385 (225 d). Tumors were trans-
planted either with or without priming into syngeneic mice, and
several generations (g) were examined, including: SIPC3301 (g1,
g2), SIPC3308 (g0, g1, g2), SIPC3282 (g0, g1, g3), SIPC3336
(g1, g2, g3, g4), and SIPC3385 (g0, g2, g3).
 
ELISA Assay.
 
SIPCs were screened for Ig secretion and Ab
activity against actin, myosin, tubulin, dsDNA, and ssDNA (5).
In brief, polystyrene flat-bottomed plates were coated with dif-
ferent Ags. After incubation with serial dilutions of each sample
in duplicate, peroxidase-conjugated anti–mouse Ig was added; di-
lution medium alone was included as the negative control. Each
assay was done in triplicate.
 
Southern Hybridization and Slot Blot Analysis.
 
Approximately
10 
 
m
 
g of EcoR1- or BamH1-digested genomic DNA was size
separated on 0.7% agarose gels. After electrophoresis, the gels
were acid (HCl) treated, alkaline treated, and neutralized in 3 M
NaCl, 0.5 M Tris-Cl, pH 7.6. Southern transfers were made to
Nytran Plus filters (Schleicher and Schuell), UV cross-linked, and
hybridized to 
 
32
 
P-labeled DNA probes at 65
 
8
 
C with a final wash
stringency of 0.2
 
3
 
 SSC at 65
 
8
 
C. The probes used to detect light
chain 
 
k
 
 rearrangements were either the 1.1-kb HindIII-XbaI (in-
tervening sequence [IVS]) or the 1.8-kb HindIII-XbaI (J
 
k
 
) frag-
ments. For heavy chain Ig rearrangements, a 0.8-kb EcoR1 J
 
H
 
probe was used. Translocation to 
 
c-Myc
 
 or 
 
Pvt 1
 
 was assayed by
screening EcoR1- or BamH1-digested filters with a 1.7-kb exon
2 PstI (
 
c-Myc
 
) or a 1.7-kb cDNA (
 
Pvt 1
 
) probe.
For slot blot hybridizations, 
 
z
 
1 
 
m
 
g of RNAs from BALB/c.
DBA/2N congenic mouse liver and spleen, as well as from each
of the SIPC tumors used in this study, were applied to Hybond
(Nycomed Amersham plc) filters and hybridized to 
 
Ly1
 
, recom-
bination activating gene 1 (
 
RAG-1
 
) cDNA, V
 
l
 
, V
 
k
 
-24, V
 
k
 
-1, or
C
 
k
 
-specific probes. After hybridization, the filters were washed at
0.2
 
3
 
 SSC at 65
 
8
 
C for 30 min.
 
Spectral Karyotyping (SKY™) of SIPC Tumors.
 
Although de-
tailed methods have been reported elsewhere (9), metaphase cells
were equilibrated in 2
 
3
 
 SSC, digested with RNase A and pepsin,
fixed in 1% formaldehyde, denatured in 70% formamide/2
 
3
 
SSC, and then dried. The fluorochromes, spectrum orange
(dUTP conjugate; Vysis), rhodamine 110 (Perkin-Elmer), and
 
Texas red (12-dUTP conjugate; Molecular Probes) were used for
direct labeling, and the haptens biotin-16–dUTP and digoxige-
nin-11-dUTP (Boehringer Mannheim Corp.) were used for in-
direct labeling. The probes were precipitated in an excess of
mouse DNA (COT-1 DNA; GIBCO BRL), and hybridized at
37
 
8
 
C for 72 h in 50% formamide/SSC/dextran sulfate. After hy-
bridization and washing (4
 
3
 
 SSC/Tween 20), the biotin was vi-
sualized by avidin-Cy5 (Nycomed Amersham plc), and the
digoxigenin-11–dUTP was visualized by mouse antidigoxigenin
(Sigma Chemical Co.) followed by sheep anti–mouse Cy5.5
(Nycomed Amersham plc). Chromosomes were counterstained
with 4,6-diamino-2-phenylindole (DAPI) and embedded in anti-
fade solution (1,4-phenylenediamine, Sigma Chemical Co.).
Spectral images were obtained on a Leica DMRBE epifluores-
cence microscope equipped with an SD200 SpectraCube
 
®
 
 (Ap-
plied Spectral Imaging) and a customized triple bandpass optical
filter. Spectrum-based classification of the raw spectral images was
performed using the software SkyView (Applied Spectral Imag-
ing).
 
Cloning and Subcloning of Rearranged V(D)J Genes.
 
Approxi-
mately 100 
 
m
 
g of genomic DNA from SIPC3336 was restricted
with EcoR1 and subjected to low-melting (1.0%) gel electro-
phoresis. Bands corresponding to the rearranged V(D)J genes
were excised, extracted with phenol, and precipitated with etha-
nol. Inserts were then ligated to either EMBL4 or 
 
l
 
gt10 arms
(EcoR1 digested). After ligation, the phage DNA was in vitro
packaged and plated to densities of 125,000 per 20 
 
3
 
 20 cm LB
plate. Benton-Davis transfer of the phage to nitrocellulose filters
was followed by hybridization to 
 
32
 
P-labeled IVS or J
 
H
 
 probes.
Positive phage were mapped by restriction endonucleases, and
inserts were subcloned into pGEM-4Z.
 
PCR Amplifications and Sequencing of Heavy and Light Chain Ig.
 
Total cellular RNA was extracted from tumor tissues by RNA
PLUS solution (Bioprobe Systems), and first-strand synthesis was
carried out as described previously (5). PCR amplifications were
set up in 50-
 
m
 
l volumes containing 10 mM Tris-HCl, pH 8.4, 50
mM KCl, 1.5 mM MgCl
 
2
 
, 200 mM of each dNTP, 2 U of Taq
DNA polymerase (GIBCO BRL), 50 pmol of each primer, and a
3 
 
m
 
l aliquot of the cDNA reaction. The primer sequences used to
amplify specific heavy chain or light chain V regions are shown in
Table I. The primers for amplification of 
 
Ly1
 
, 
 
RAG-1
 
, and
 
RAG-2
 
 are as follows: CCTAGATATCCAGGTGGT (Ly1 5
 
9
 
),
GTGTCCTGGCACCAGCTG (Ly1 3
 
9
 
), AGGATCTGCA-
TTCTCAGA (RAG-1 5
 
9
 
), TCAGCTTGCCTGTGCTCA
(RAG-1 3
 
9
 
), GTCTCCAACAGTCAGACA (RAG-2 5
 
9
 
), and
GCTCTTGCTATCTGTACA (RAG-2 3
 
9
 
).
Each PCR amplification product was purified by agarose gel
electrophoresis, extracted, and then subcloned into the TOPO-
TA vector following the manufacturer’s protocol (Invitrogen).
Single bacterial colonies were isolated for direct sequencing. Se-
quencing was carried out according to the manufacturer’s proto-
col (Promega). The nucleotide sequence data were analyzed, and
comparisons were made with MacVector or Genetics Computer
Group (GCG) software packages.
 
Results
 
SIPC Tumors Display Polyreactivity.
 
The ascites fluid of
33 different SIPC tumors was assessed for binding activity
against actin, myosin, tubulin, ssDNA, and dsDNA by
ELISA (10). We have focused on purified Abs from five of
these tumors, each of which binds to at least one of the Ags 
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from the panel. As far as heavy chain class, four out of the
five SIPCs examined (SIPC3308, SIPC3301, SIPC3336,
and SIPC3282) in this study expressed IgA (only SIPC3385
expressed IgG3). Although most Abs show higher reactiv-
ity to myosin, several are particularly reactive to dsDNA
and ssDNA. The tumor SIPC3301 displays low reactivity
with essentially all Ags on this panel. The SIPC3282,
SIPC3308, SIPC3336, and SIPC3385 Abs were found to
display a polyreactive binding activity (Table II).
 
Cytogenetics of SIPC Tumors.
 
Cytogenetic studies have
revealed that a majority of PCs contain reciprocal T(12;15)
translocations (1). Alternatively, several SIPC tumors ex-
hibit a reciprocal T(6;15) translocation (considered to be
the variant translocation), as demonstrated by the SKY™
analysis performed on two representative SIPC tumors
(Fig. 1). While SKY™ cytogenetics is a good indicator of
T(12;15) or T(6;15) translocations, it is not entirely certain
whether 
 
c-Myc
 
 or 
 
Pvt 1
 
 is targeted by these translocations,
as we have only found two SIPC tumors with 
 
c-Myc
 
 rear-
rangements (SIPC3385, SIPC3301) and no tumors with
 
Pvt 1
 
 rearrangements at the Southern hybridization level
(Table III, and Fig. 2). The assay for molecular rearrange-
ment is based on utilization of a series of hybridization
probes surrounding the major breakpoints of 
 
Pvt 1
 
 or 
 
c-Myc
 
,
and by incorporating large restriction fragments into the
analyses (11). The absence of detectable rearrangements
with 
 
Pvt 1
 
 or 
 
c-Myc
 
 in such a large number of SIPC tumors
(Table III, and data not shown) suggests that, in general,
SIPC-associated translocations could reside outside the
usual or more common breakpoint locations, and may not
be detectable with the probes used in this study.
 
Ig V
 
H
 
 Gene Expression.
 
Initially, Ig heavy chain–specific
rearrangements were identified in each tumor by Southern
blot analysis using a J
 
H
 
 probe (Fig. 3). Heavy chain-specific
rearrangements were found in all tumors, including appar-
ent rearrangements of both alleles in SIPC3385, SIPC3282,
and SIPC3301. We also found shared rearrangements with
both BamH1 (not shown) and EcoR1 digestions in
SIPC3308, SIPC3336, and SIPC3282, suggesting the same
V
 
H
 
 gene may be expressed in these tumors. We cloned and
sequenced the 3.5-kb EcoR1 fragment from SIPC3336,
and established that the rearrangement consists of a mem-
 
Table I.
 
Primer Sequences Used in V Region–specific
PCR Amplifications
 
V region primers
V
 
H
 
-SG1 GTGCAGCTKMAGSAGTCRGG
V
 
H
 
-SG2 CARCTGCARCARYCTGG
V
 
H
 
-SG3 GTGAAGCTKSWSGARTCTGG
V
 
H
 
-SG4 GTYCARCTKCARCAGTCTGG
V
 
H
 
13-3-5
 
9
 
GCTGAACTGGCAAAACCT
V
 
H
 
13-3-3
 
9
 
GTAATAGACTGCAGAGTC
V
 
k
 
1-FW1 AGTCTTGGAGATCAAGCC
V
 
k
 
24-CDR1 TCCTGCAGGTCTAGTAAG
V
 
k
 
24-FW3 GCCTCAGGAGTCCCAGAC
V
 
k
 
1,2 ATGTTGTGATGACCCA
V
 
k
 
4,5 AAATTGTTCTCACCCA
V
 
k
 
8,14,15,19,21 ACATTGTGMTGACHCA
V
 
k
 
9,12,13,31,
33,34 ACATCCAGATGACHCA
V
 
k
 
20 AAACAACTGTGACCCA
Vk
 
k
 
23 ATATTGTGCTAACTCA
V
 
k
 
24,28 RTATTGTGATGACYCA
V
 
l
 
TTCCCAGGCTGTTGTGA
C region primers
J
 
H
 
3 GCAGAGAATCTTGGTCCT
IgG3 GTCACTGCAGCCAGGGACCA
IgA GATGGTGGGATTTCTCGCAGACTC
IgGX CAGGGGCCAGTGGATAGAC
J
 
k
 
2 CCTTAACACTTGATCTGA
J
 
k
 
4 CTATTGATGCACAGGTTG
C
 
k
 
ACACTCATTCCTGTTGAA
C
 
l
 
GAGCTCTTCAGAGGAAGG
 
Table II.
 
Reactivity Pattern of SIPC-purified Abs against Various Antigens
 
Abs Isotype
Antigen activity as measured by ELISA
 
*
 
Actin Myosin Tubulin dsDNA ssDNA
SIPC3385 IgG3 390 
 
6
 
 19.519 845 6 31 869 6 12.529 1,632 6 368.501 1,835 6 1
SIPC3308 IgA 362 6 1.732 1,178 6 3.785 145 6 17 287 6 8.544 638 6 8.504
SIPC3301 IgA 219 6 41.501 250 6 31 56 6 7.549 188 6 5 240 6 34
SIPC3336 IgA 143 6 1 1,253 6 4 60 6 2.645 126 6 0 195 6 12
SIPC3282 IgA 924 6 1 1,224 6 2.081 454 6 145.502 1,505 6 64 1,978 6 81
*Antigen-coated plates were incubated with purified Abs (1 mg/ml) or dilution medium, and then were incubated with a peroxidase anti–mouse IgA or
IgG3 conjugate. The enzyme activity was detected at 450 nm, and the results are expressed in optical densities. Results are the average of triplicates 6 SD.1408 Ig Genes and Secondary Rearrangements in Plasmacytomas
ber of the VH-J558 family (H13-3; reference 12) rearranged
to DHSP2-9 and JH3. To more specifically determine VH
gene usage in the SIPC tumors, we examined the expressed
sequences by reverse transcription (RT)-PCR (Fig. 4). In-
deed, three of the SIPC tumors (SIPC3282, SIPC3336,
and SIPC3308) that share the 3.5-kb EcoR1 rearrange-
ment all use the same H13-3 gene from the VH-J558 fam-
ily. We verified that this sequence was germline (nonmu-
tated) by sequencing eight clones derived from the PCR
product of BALB/c genomic DNA which was amplified
by primer pairs specific for H13-3 (see Table I). Interest-
ingly, these same three tumors have also rearranged to JH3,
and use the same DH region (DHSP2-9) encoding the
amino acid residues Trp-Phe. Although rearranged to JH3
and DHSP2-9 as well, SIPC3301 has a longer nucleotide
addition sequence, and is in fact encoded by another mem-
ber (26.4.1-a; reference 13) of the VH-J558 family. The
RT-PCR product of SIPC3385 was also found to use a
member of the VH-J558 family, but in this case the nitro-
phenyl-binding 4m3 VH gene (14). In SIPC3385, the rear-
rangement involves JH4 and another member of the DHSP2
family with N sequence additions. Analysis of the VH re-
gion sequences reveals somatic mutational activity with
high replacement to silent (R/S) ratios, since all the SIPCs
that express H13-3 exhibit four to six replacement changes
with no accompanying silent base changes (Fig. 4). In the
case of SIPC3385, we only find a single replacement in VH.
Ig VL Gene Expression. We examined the light chain–
specific rearrangements of the SIPC tumors at the Southern
hybridization level. The tumors SIPC3308, SIPC3336, and
SIPC3282 all shared identical rearrangements with both
EcoR1 (Fig. 5) and BamH1 (data not shown) digestions.
By cloning and sequencing the 18-kb EcoR1 fragment
(from SIPC3336), we obtained a Vk24C-Jk4 (15) sequence
suggesting that SIPC3308, SIPC3336, and SIPC3282 may
all share the same rearrangement. When we performed
PCR amplifications in each of these tumors with primers
specific for Vk24C and Jk4, we obtained positive products
that were identical as well as nonmutated (Fig. 6). To test
whether the Vk24C-Jk4 rearrangement is productive (ex-
pressed), we used Vk24C and Ck–specific primers in RT-
PCR assays, and again, found positive products in each of
Figure 1. SKY™ images of SIPC tumors with variant T(6;15) chro-
mosomal translocations, (A) SIPC3308 and (B) SIPC3282. The arrows
mark chromosomal translocations that have occurred between CHR6
(yellow) and CHR15 (blue). There are two copies of each T(6;15) and
the reciprocal T(15;6).
Table III. Cytogenetics of SIPC Tumors
Tumors
SKY™
analysis
Molecular
rearrangement*
SIPC3385 T(12;15) c-Myc (18 kb)
SIPC3308 T(6;15) NR‡
SIPC3301 T(12;15) c-Myc (18 kb)
SIPC3336 T(6;15) NR
SIPC3282 T(6;15) NR
*Assayed by digestion with EcoR1 (c-Myc) or BamH1 (Pvt 1).
‡No rearrangement (NR) with either c-Myc or Pvt 1.
Figure 2. Southern hybridization assay for c-Myc and Pvt 1 rearrange-
ments in SIPC tumors. Shown top (c-Myc, EcoR1) and bottom (Pvt 1,
BamH1) are the following tumors: lane 1, SIPC3385; lane 2, SIPC3308;
lane 3, SIPC3301; lane 4, SIPC3336; lane 5, SIPC3282; and lane 6,
BALB/c. Arrows depict the germline (nonrearranged fragments). Two
samples (SIPC3385 and SIPC3301) contain rearranged bands with c-Myc,
whereas no rearrangements are found with Pvt 1.1409 Diaw et al.
these tumors (data not shown). Although the nature of
the common 9.5-kb EcoR1 band found in SIPC3308,
SIPC3336, and SIPC3282 is uncertain at the moment, we
do know it must be related to the rearrangement to
Vk24C-Jk4, since they are always found in association with
the productive rearrangement in each of these tumors.
Southern blots with a Ck only (minus IVS) probe result in
no hybridization to the 9.5-kb EcoR1 band, proving this
fragment to be nonproductive and probably a byproduct of
the rearrangement process (data not shown). Both SIPC3385
and SIPC3301 exhibit different rearrangements at the South-
ern blot level. Therefore, we performed RT-PCR amplifi-
cations to determine the expressed Vk gene for these two tu-
mors as well. The tumor SIPC3385 was found to express a
nonmutated Vk21G-Jk2 sequence (16), whereas SIPC3301
expressed a nonmutated Vk34C-Jk2 sequence (17).
In the process of verifying the expressed Vk sequences
discussed above, we subjected all the SIPC tumors to RT-
PCR amplification using sets of primers (Table I) that were
cross-reactive to each of the Vk and Vl gene families. Un-
expectedly, we found that in addition to expression of
Vk24C-Jk4, Vk21G-Jk2, and Vk34C-Jk2, each of the SIPC
tumors expressed an additional Igk or Igl light chain gene, a
finding in violation of allelic exclusion normally associated
with Ab gene expression (18–20). All the SIPC tumors ex-
amined in this study were found to express either Vk1A or
Vk1C (21, 22) rearranged to either Jk1, Jk2, or Jk4 segments
Figure 3. JH rearrangements in SIPC tumors. Genomic DNAs from
SIPC tumors and BALB/c liver were digested with EcoR1 and hybridized
with the JH probe: lane 1, SIPC3385; lane 2, SIPC3308; lane 3, SIPC3301;
lane 4, SIPC3336; lane 5, SIPC3282; and lane 6, BALB/c. An arrow (left)
depicts the germline (nonrearranged) JH fragment, whereas the 3.5-kb
EcoR1 rearrangement seen in several tumors is also highlighted.
Figure 4. Nucleotide sequences of VH genes from SIPC tumors. The se-
quences obtained with the five SIPC tumors have been compared with the
most homologous germline genes which are members of the VH-J558 fam-
ily. Top: SIPC3336, SIPC3308, and SIPC3282 express VH13-3; middle:
SIPC3301 expresses 26.4.1-a; bottom: SIPC3385 expresses 4ma. Dashes
indicate sequence identities. Germline amino acids in bold indicate that
they are replaced in SIPCs. These sequence data are available from EMBL/
GenBank/DDBJ under accession nos. AF154880–AF154882, AF154909,
and AF154910.
Figure 5. IgL rearrangements of SIPC tumors. Genomic DNAs from
SIPC tumors and BALB/c liver were digested with EcoR1 and hybrid-
ized with the IVS probe: lane 1, SIPC3385; lane 2, SIPC3308; lane 3,
SIPC3301; lane 4, SIPC3336; lane 5, SIPC3282; and lane 6, BALB/c. An
arrow (left) depicts the germline (nonrearranged) Igk fragment, whereas
the 18 and 9.5-kb EcoR1 rearrangements seen in SIPC3308, SIPC3336,
and SIPC3282 are also highlighted (right).1410 Ig Genes and Secondary Rearrangements in Plasmacytomas
(Fig. 7). Furthermore, we also found that both Vk1C se-
quences and Vk1A sequences exhibited some level of so-
matic mutation (as found in the VH above). With a 1:1 R/S
ratio for the whole V region (and a higher R/S ratio in
CDR2) in Vk1A, only minimal levels of Ag selection are
evident. We also found three tumors, SIPC3282, SIPC3301,
and SIPC3336, that express Vl1-Cl1 sequences (Fig. 8). In
this instance, these sequences are mutated (all changes are
replacements), and there is evidence of clonal divergence.
Interestingly, no Vl sequences were found in SIPC3385 or
SIPC3308. This later result is important, as it is a critical
distinction between SIPC3308 and SIPC3336.
Transcript Levels of Igk and Igl in SIPC Tumors. Levels of
Igk and Igl were compared by slot blot hybridization using
specific probes for Vk1, Vk24, Vl, and Ck (Fig. 9). Interest-
ingly, SIPC3301 expressed high levels of Igl, whereas
SIPC3385 expressed high levels of Vk1. Consistently, both
SIPC3282 and SIPC3336 expressed high levels of both Vk1
Figure 6. Nucleotide sequence of the Vk24C-Jk4 gene from the SIPC
tumors. Sequences obtained from SIPC3282, SIPC3336, and SIPC3308
(bottom line) have been compared to that of the germline Vk24C (refer-
ence 15). Dashes indicate sequence identities. Substitutions at the amino
acid level are indicated in bold. These sequence data are available from
EMBL/GenBank/DDBJ under accession no. AF154911.
Figure 7. Nucleotide se-
quences of Vk1 genes expressed
in SIPC tumors. Sequences were
obtained from individual clones
(designated A–F) of SIPC3282,
SIPC3301, SIPC3336, SIPC3308,
and SIPC3385. Although multi-
ple subclones with identical se-
quences were obtained, only
representative sequences that dif-
fer are shown. The sequences are
compared with the most homol-
ogous germline gene K5.1 (Vk1A,
top) or K1A5 (Vk1C, bottom).
Dashes indicate sequence identi-
ties, and amino acid substitu-
tions are indicated in bold.
These sequence data are avail-
able from EMBL/GenBank/
DDBJ under accession nos.
AF154883–AF154898.1411 Diaw et al.
and Vk24. Since there is evidence that peritoneal cavity B
cells are enriched in B-1 cells, we also tested for Ly1 ex-
pression by RT-PCR amplification of total RNA from
thymus, spleen, two PCs, (ABPC18, MOPC104E) and the
SIPC tumors. Although expression of Ly1 was found in
thymus, spleen, and the two conventional PCs, no expres-
sion of Ly1 was evident in the SIPC tumors (data not
shown). RAG-1 (data not shown) and RAG-2 (Fig. 9) ac-
tivity, both of which have recently been found in the pe-
ripheral B-1 population (23), were also independently as-
sayed by RT-PCR amplification among similar panels of
RNAs. Both RAG-1 and RAG-2 expression were found in
thymus, spleen, SIPC3301, SIPC3308, SIPC3385, ABPC18,
and MOPC104E, but not in SIPC3282 or SIPC3336.
Discussion
Since spontaneous PCs occur rarely in mice, studies in
plasmacytomagenesis rely on induction models. All PCs arise
in the peritoneum, where the presence of nonmetabolizable
paraffin oils (pristane) or plastic implants induces chronic in-
flammation, granuloma formation, and finally development
of the PC (1). The SIPC may differ by having fewer num-
bers of atypical foci (8). Binding studies of pristane-induced
PCs showed that PCs can display binding activities against
phosphorylcholine, various dextrans, and fructofuranans (2).
The SIPCs, as we show in this study, possess a set of binding
specificities against cytoskeletal proteins and DNA. In fact, in
the initial panel of ascites from 33 SIPC tumors, binding ac-
tivity against at least 1 of the Ags of the panel, and most often
polyreactive binding activity, is commonly observed. To as-
certain whether the SIPC tumors possess a characteristic set
of binding properties and whether these binding specificities
could assist in identifying a precursor cell population, we fo-
cused on the binding activity of purified proteins from five
representative SIPC tumors.
Figure 8. Nucleotide sequences of Vl1
genes expressed in SIPC tumors. Nucleotide
sequences of subclones (designated A–F) of Vl
genes from SIPC3282, SIPC3336, and
SIPC3301 are compared with the most ho-
mologous germline gene. Dashes indicate se-
quence identities, and amino acid substitutions
are indicated in bold. These sequence data are
available from EMBL/GenBank/DDBJ under
accession nos. AF154899–AF154908.
Figure 9. Transcript levels of Igk, Igl, and RAG-2 in SIPC tumors. (Top)
Equal amounts of RNA from mouse liver (lane 1), spleen (lane 2), SIPC3301
(lane 3), SIPC3308 (lane 4), SIPC3282 (lane 5), SIPC3336 (lane 6), and
SIPC3385 (lane 7) were loaded into slots and hybridized to nick-translated
probes from Vk24 (row 1), Vk1 (row 2), Ck (row 3), or Vl (row 4). (Bot-
tom) RNA from mouse spleen (lane 1), thymus (lane 2), SIPC3282 (lane
3), SIPC3301 (lane 4), SIPC3308 (lane 5), SIPC3336 (lane 6), SIPC3385
(lane 7), ABPC18 (lane 8), and MOPC104E (lane 9) was reverse tran-
scribed (RT) and PCR amplified using primers specific for RAG-2.1412 Ig Genes and Secondary Rearrangements in Plasmacytomas
We have found that three independent SIPC tumors, each
derived from different generations (SIPC3282, SIPC3308,
and SIPC3336), share identical VH domains including DH
and JH regions (Table IV). Several facts argue strongly in fa-
vor of the independent derivation of these tumors: (a) each
tumor was harvested at different times as a result of variable
latency periods (see Materials and Methods); (b) reactivity
patterns differ between each tumor (Table II); (c) SIPC3282
shows an additional rearrangement (JH) not found in other
tumors, as well as additional somatic mutations not found in
other tumors; (d) SIPC3385 and SIPC3308 both lack Vl1
rearrangements; and (e) no RAG-1/2 expression is found in
SIPC3282 or SIPC3336. These results also support the exist-
ence of a strong restriction in V gene usage for the SIPCs.
These results are in contrast with reports for human my-
eloma, where no particular selection for V genes has been
observed (24). In contrast, Waldenström macroglobulinemia
patients exhibiting rheumatoid or cold agglutinin anti-I
specificities exhibit a strong restriction for V genes, as the
V1-69 VH1 gene member is almost constantly expressed in
the case of cryoglobulins expressing the WA recurrent idio-
type (60% of cases), and the V4-34 (VH4-21) gene is con-
stantly expressed by cold agglutinins with anti-I specificity
(95% of cases; [25]). Although the DH region is not identical
among these Abs, a report by Fais et al. (26) shows that
among 50% of CLL patients expressing the 1-69 gene, the
DH3-3 region is used. In addition, a report from the same
group indicated that five different cases of CD51IgG1 CLLs
expressed virtually identical Ag receptors, by recombining
(unmutated) the VH-4-39 gene to D6-13-JH5b and the
Vk012 gene to Jk1 (27).
Ig gene assembly is an ordered process that begins with
heavy chain gene rearrangement (28) under the regulation
of recombinase genes (RAG-1/RAG-2). As the Ig rear-
rangement process is error prone, only a successful V(D)J
assembly leads to pre-B cell receptor assembly (29, 30) and
eventual downregulation of RAG-1/RAG-2 activity (31).
Further differentiated and proliferating B cells reactivate
the recombinases to rearrange the light chain genes, which
once again are error prone, i.e., wherein only successful re-
arrangement leads to maturation rather than cell death (29,
30). Therefore, allelic exclusion, typically the hallmark of
Ig gene expression and of an active process, may also stem
more from the low frequency of productive or successful
rearrangement. With the elucidation of V gene receptor
editing (32–38), we now know that lymphocytes express-
ing self-reactivity in the bone marrow, germinal center
(GC), or even in the periphery can be rescued from cell
death by exchanging already rearranged V regions with
other available V genes through reactivation of the RAG-
1/RAG-2 recombination pathway (23, 38–40). It has been
shown that recombinase activity is stimulated by low-affin-
ity Abs and is inhibited by high-affinity Abs (41), and ac-
cordingly, secondary Ig rearrangements actually occur quite
frequently (42–45). RAG-1/RAG-2 activity is also found
in GC B cells bearing low-affinity receptors, or in periph-
eral B-1 cells (23). Indeed, there is increasing evidence that
productive and successful light chain rearrangements do not
effectively arrest further rearrangement (46–52). Thus, one
would then expect frequent violations of allelic exclusion
in that k:l dual expressors (53), as well as dual expressors of
Igk (54, 55) subtype, should be quite common.
In this study of SIPC tumors, we have observed only a
single productive rearrangement of the light chain genes at
the Southern hybridization level for Vk24C-Jk4. For
SIPC3385 (expressing Vk21G-Jk2) and SIPC3301 (express-
ing Vk34C-Jk2), we find rearrangements in both EcoR1
and BamH1 Southern blots that are, in fact, consistent with
predicted sizes from germline restriction maps for both Vk
and Jk gene segments (16, 17). We only detected second-
arily expressed alleles (k or l) by RT-PCR at levels below
the Southern detection levels, i.e., subthreshold. We can
eliminate contaminating host tissue as contributing to this
observation by several lines of argument. (a) A restricted
subset (Vk1 or Vl1) of V genes are found, rather than sim-
ply random usage. Furthermore, since Vl1 is rarely ex-
pressed in the mouse, finding Vl1 in 3/5 tumors is highly
unlikely. (b) We have recently colinked Vk24 and Vl1 ex-
pression at the single cell level by RT-PCR amplification
(our unpublished results). A more likely explanation, there-
fore, is that we must be observing only a subset of B cells in
these tumors expressing both alleles. Thus, the presence of
dual expressing k:l or k:k alleles indicates that secondary
rearrangements are occurring in the SIPC tumors, but
whether this rearrangement occurs at significant levels to
alter the tumor reactivity patterns must be considered fur-
ther. Interestingly, it is conceivable that the Vk24C-Jk4 re-
arrangement that is shared by three of the tumors may al-
ready be an example of secondary rearrangements after a
Table IV. Heavy and Light Chain Gene Usage in SIPC Tumors
Tumors
Expressed
heavy chain
Expressed
light chain
12 3
SIPC3385 4m3- Vk21G-Jk2V k1A-Jk1
DSP2- Vk1C-Jk2
JH4*
SIPC3308 H13-3- Vk24C-Jk4V k1A-Jk1
DSP2-9- Vk1C-Jk1
JH3* Vk1C-Jk2
SIPC3301 26.4.1.a-V k34C-Jk2V k1A-Jk1V l1-Cl1
DSP2-9- Vk1A-Jk4
JH3*
SIPC3336 H13-3- Vk24C-Jk4V k1A-Jk4V l1-Cl1
DSP2-9- Vk1C-Jk2
JH3* Vk1C-Jk4
SIPC3282 H13-3- Vk24C-Jk4V k1A-Jk2V l1-Cl1
DSP2-9-
JH3*
*VH-J558 family.1413 Diaw et al.
highly selectable process, as secondary rearrangements of
the same allele are often characterized by upstream Vk seg-
ments associated with downstream Jk segments. An alterna-
tive explanation, that the observed biallelic expression arises
from an outgrowth of a subset of tumor cells, cannot for-
mally be discounted. Indeed, when we compare the reac-
tivities (Table II) of two SIPC tumors (SIPC3308,
SIPC3336) that exhibit identical Vk24C-Jk4 and V(D)J re-
arrangements, including amino acid substitutions, we find
greater reactivity to ssDNA with SIPC3308. Thus, a per-
ceived difference in reactivity between these tumors may
stem from the “subthreshold” levels of Vk1 or Vl. These
“subthreshold” rearrangements do not necessarily have to
occur in the bone marrow or GC, but could occur in the
periphery where RAG-1/2 can be reactivated (56). How-
ever, as recent studies suggest that RAG-1/2 activity may
not actually be reinduced, but may reflect differing levels of
B cell development (57), we may be observing a small self-
renewing B cell population in the tumors presented here.
Interestingly, we find RAG-1/2 still active in most of the
SIPCs, with the exception of two tumors (SIPC3336 and
SIPC3282), both of which also express IgVl.
The precursor to PCs has long been thought to be the
B-1 cell through two lines of evidence: (a) B-1 cells are
most abundant in the peritoneum, and are associated pri-
marily with IgA in the lamina propria (58); and (b) in addi-
tion to dextran, phosphorylcholine is one of the more
common Ags associated with the gut flora and is dominated
by the T15 idiotype (1). It has been shown by X-irradia-
tion and failure to regenerate the T15 idiotype by bone
marrow reconstitution (59, 60) that the T15 idiotype can
only be restored by peritoneal B cells (i.e., B-1 cells).
While B-1 cells express Ly1, it is uncertain as to whether
Ly1 is activated as a consequence of immortalization, or
whether this represents a distinct B cell lineage. We have
determined that several pristane-induced PCs (including
M104E and ABPC18) express Ly1 by RT-PCR amplifica-
tion. Conversely, we have found that the SIPC tumors do
not express Ly1, but further studies will be needed to rigor-
ously determine whether the SIPCs are truly B-1a, B-1b,
or even B-2 cells.
We now show that the SIPC tumors exhibit secondary
Ig light chain gene rearrangements (and accompanying
RAG-1/2 activity), exhibit low levels of somatic mutation
in Vk or Vl, and show some evidence of clonal heterogene-
ity. While B-2 cells are mutated and most frequently found
in the GC, the B-1 population is most often found in the
mantle zone with few somatic mutations (61). The fact that
we find evidence of tumors bearing somatic mutations with
intraclonal heterogeneity and with high R/S ratios suggests
Ag selection is occurring. V region analysis in several tumor
systems besides SIPCs, including Burkitt’s lymphoma (62,
63), diffuse large cell lymphoma (64), mantle cell lym-
phoma (65), and follicular lymphomas (64), demonstrates
clonal heterogeneity in that somatic mutations appear to be
ongoing during the progression of the tumor. Temporally,
many of these tumors arise at different stages of lymphoid
maturation and in different lymphoid compartments. In
contrast, more mature tumors such as multiple myeloma
(66, 67) and pristane-induced mouse PCs (2) have tradi-
tionally been found to exhibit homogeneous Abs, suggest-
ing that these transformed cells must have been immortal-
ized post-GC. Based on these findings, we propose that the
SIPC tumors may have become an immortalized B cell
population in the periphery.
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